Onier N, Lejeune P, Martin M, Hammann A, Bauer J, Hirt P, Lagadec P, Jeannin J F
INSERM, U 252, faculté de médecine, Dijon, France.
Eur J Cancer. 1993;29A(14):2003-9. doi: 10.1016/0959-8049(93)90462-o.
In a model of colon cancer in syngeneic rats, a new immunomodulator, OM 163, induced the complete disappearance of peritoneal carcinomatosis (nodules measuring 1-5 mm) in 41 out of 82 rats. Those results were confirmed in a survival experiment in which 3 out of 10 treated rats died free of tumour 10, 18 and 28 months after the tumour cell injection while all the untreated control rats died of their tumours within 3 months. OM 163 had a systemic effect, since injected intraperitoneally it completely inhibited the growth of lung metastases in 13 out of 20 rats. The antitumour effect of OM 163 was also observed in two rat strains on original tumours. Lymphocyte infiltration was observed in the tumours mainly constituted of CD4+ and CD8+ cells. The treatment had no effect in nude rats, confirming the involvement of T lymphocytes. Furthermore, rats cured by OM 163 were protected against a second challenge of tumour cells and in a Winn's assay, splenocytes from cured rats protected normal rats against tumour cells.
在同基因大鼠结肠癌模型中，一种新型免疫调节剂OM 163使82只大鼠中的41只腹膜癌（结节大小为1 - 5毫米）完全消失。这些结果在一项生存实验中得到证实，在该实验中，10只接受治疗的大鼠中有3只在注射肿瘤细胞后10、18和28个月时无瘤存活，而所有未治疗的对照大鼠在3个月内死于肿瘤。OM 163具有全身作用，因为腹腔注射后，它使20只大鼠中的13只肺部转移瘤的生长完全受到抑制。在两种大鼠品系的原发肿瘤上也观察到了OM 163的抗肿瘤作用。在主要由CD4 +和CD8 +细胞组成的肿瘤中观察到淋巴细胞浸润。该治疗对裸鼠无效，证实了T淋巴细胞的参与。此外，经OM 163治愈的大鼠对肿瘤细胞的二次攻击具有抵抗力，并且在温氏试验中，治愈大鼠的脾细胞可保护正常大鼠免受肿瘤细胞侵害。
